Defined Schwann Cell Differentiation for High-Fidelity Disease Models
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Access to authentic models of human Schwann cells at large scale is a major challenge for understanding and addressing genetic and acquired peripheral nervous system disorders such as Charcot-Marie-Tooth disease, Schwannomatosis, Guillain-Barre Syndrome, and diabetic peripheral neuropathy, as current models lack fidelity and effective therapies.
Innovation Solution
A method of differentiating pluripotent stem cells into Schwann cells using defined conditions, including exposure to FGF2 and WNT pathway activators, and culturing them to achieve high purity, with markers like CD98 and SOX10 expression, for use in therapeutic screening and regenerative medicine.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If pluripotent stem cells are differentiated into Schwann cells using conventional methods, then Schwann cells can be obtained for research, but the purity and authenticity of the Schwann cell models are insufficient
Solution Approach 1:
The patent applies parameter changes by optimizing differentiation conditions including specific growth factors (FGF2, EGF, bFGF), cytokines (SCF, IGF-1), and culture media compositions at defined concentrations and timepoints. This systematic parameter optimization achieves high-purity Schwann cell differentiation while maintaining model fidelity for disease research
Solution Approach 2:
The patent uses intermediary molecules including growth factors and cytokines as mediators to guide pluripotent stem cell differentiation into Schwann cells. These intermediaries (FGF2, EGF, SCF, IGF-1) facilitate the transformation process while maintaining cell authenticity and purity
2Quantity of substance
If large-scale Schwann cell models are produced, then sufficient material for research is available, but current models lack the authenticity required for reliable disease modeling
Solution Approach 1:
The patent employs parameter changes by scaling up culture conditions while maintaining optimized differentiation parameters (growth factor concentrations, culture timepoints, media composition). This enables large-scale production of authentic Schwann cells that retain disease-modeling fidelity
Solution Approach 2:
The patent applies preliminary action by pre-optimizing differentiation protocols and culture conditions before scaling up production. This ensures that when large quantities of Schwann cells are produced, they maintain high authenticity and reliability for disease research applications
3Manufacturing precision
If Schwann cells are cultured for extended periods to achieve high purity, then cell quality improves, but culture time and resource requirements increase
Solution Approach 1:
The patent applies continuity of useful action by implementing sustained culture conditions with continuous supplementation of growth factors and cytokines at optimized concentrations. This maintains differentiation efficiency and cell purity over the required culture period without premature cell death or differentiation arrest
Solution Approach 2:
The patent uses parameter changes by optimizing culture timepoints and media replacement schedules to achieve high purity Schwann cells at the earliest possible timepoint. This reduces unnecessary culture duration while maintaining quality standards
Data Source
AI summary
The present disclosure relates generally to methods and systems of producing Schwann cells from pluripotent stem cells under fully defined conditions. The Schwann cells produced by the disclosed methods find applications as models of the enteric nervous system, tools for high throughput screening of potential therapeutics for treatment of enteric neuropathies, and in regenerative medicine.